ESSA Pharma Inc (TSX-V: EPI;Nasdaq: EPIX), a Canada-based pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer, has granted incentive stock options to directors and officers, employees and consults of the Corporation to purchase up to an aggregate of 238,000 common shares in the capital of the Corporation, it was reported on Friday.
Such stock options will vest in 48 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date.
The stock options are exercisable on or before 8 February 2029 at the price of USD3.81 per common share and are offered in accordance with the policies of the TSX Venture Exchange and the terms and conditions of the corporation's stock option plan.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma